Corient Capital Partners’s Halozyme HALO Stock Holding History

Corient Capital Partners’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$204K	Hold	4,627	–	–	0.02%	611
2022 Q2	$204K	Buy	+4,627	New	+$200K	0.02%	625

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corient Capital Partners's HALO Position: Q3 2022 in Review

Corient Capital Partners held its Halozyme (HALO) position steady in Q3 2022 at 4,627 shares worth $204K. The position accounts for 0.02% of the portfolio, ranked #611.

Corient Capital Partners first reported a position in HALO in Q2 2022 and has held it in 2 quarters since. 357 funds tracked by Wall St. Rank hold HALO as of Q3 2022.

Corient Capital Partners held 4,627 shares of Halozyme worth $204K as of Q3 2022.
Corient Capital Partners left its Halozyme share count unchanged in Q3 2022.
Halozyme made up 0.02% of Corient Capital Partners's portfolio in Q3 2022, its #611 holding.
Corient Capital Partners first reported a position in Halozyme in Q2 2022 and has held it in 2 quarters since.
357 funds tracked by Wall St. Rank held Halozyme as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.